Highland Private Wealth Management’s Colgate-Palmolive CL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-3,340
Closed -$234K 32
2022
Q3
$234K Buy
3,340
+75
+2% +$5.88K 0.04% 163
2022
Q2
$261K Buy
3,265
+119
+4% +$9.3K 0.04% 145
2022
Q1
$239K Buy
3,146
+40
+1% +$3.17K 0.03% 164
2021
Q4
$265K Sell
3,106
-2,339
-43% -$183K 0.03% 155
2021
Q3
$412K Buy
5,445
+2,478
+84% +$197K 0.06% 109
2021
Q2
$241K Buy
2,967
+21
+0.7% +$1.72K 0.04% 153
2021
Q1
$232K Sell
2,946
-82
-3% -$6.43K 0.04% 143
2020
Q4
$259K Buy
3,028
+50
+2% +$4.13K 0.04% 122
2020
Q3
$229K Sell
2,978
-123
-4% -$9.38K 0.05% 118
2020
Q2
$228K Buy
+3,101
New +$220K 0.05% 117
2018
Q1
Sell
-2,560
Closed -$193K 114
2017
Q4
$193K Buy
+2,560
New +$187K 0.08% 95
2016
Q4
Sell
-3,051
Closed -$226K 82
2016
Q3
$226K Buy
3,051
+191
+7% +$14.1K 0.12% 65
2016
Q2
$209K Buy
2,860
+14
+0.5% +$997 0.12% 69
2016
Q1
$200K Buy
+2,846
New +$189K 0.12% 69

Other funds holding CL

Highland Private Wealth Management's CL Position: Q4 2022 in Review

Highland Private Wealth Management sold out of Colgate-Palmolive (CL) in Q4 2022, closing a stake of 3,340 shares — an estimated $234K sold.

Highland Private Wealth Management first reported a position in CL in Q1 2016 and held it in 14 quarters. The position peaked at $412K in Q3 2021. 1,699 funds tracked by Wall St. Rank hold CL as of Q4 2022.

  • Highland Private Wealth Management reported no remaining Colgate-Palmolive position as of Q4 2022 after selling out during the quarter.
  • Highland Private Wealth Management sold 3,340 Colgate-Palmolive shares in Q4 2022, an estimated $234K.
  • Highland Private Wealth Management first reported a position in Colgate-Palmolive in Q1 2016 and held it in 14 quarters.
  • Highland Private Wealth Management's Colgate-Palmolive position peaked at $412K in Q3 2021.
  • 1,699 funds tracked by Wall St. Rank held Colgate-Palmolive as of Q4 2022.

Based on Highland Private Wealth Management's 13F filing for Q4 2022.